IN8bio, Inc. (INAB)Healthcare | Biotechnology | New York, United States | NasdaqCM
1.44 USD
-0.01
(-0.690%) ⇩
(April 17, 2026, 4 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:57 p.m. EDT
IN8bio, Inc. (INAB) is a high-risk, low-reward stock with a volatile price history and no dividend payouts. The stock has been trading below its 50-day and 200-day moving averages, indicating weak momentum. The recent price movements suggest a lack of consistent upward trends, and the company's fundamentals are weak, with negative earnings and a low price-to-book ratio. While there are some positive news headlines, the overall outlook for short-term trading is bearish, and long-term investment potential is limited. This stock is not suitable for dividend-focused investors or those seeking stable returns. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.300377 |
| AutoARIMA | 0.300379 |
| MSTL | 0.302551 |
| AutoTheta | 0.370166 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 5.92 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.667 |
| Excess Kurtosis | -0.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.095 |
| Market Cap | 14,179,810 |
| Forward P/E | -0.96 |
| Beta | 0.04 |
| Website | https://in8bio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.70883536 |
| Address1 | 350 5th Avenue |
| Address2 | Suite 5330 |
| All Time High | 309.57 |
| All Time Low | 1.17 |
| Ask | 1.48 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 53,620 |
| Average Daily Volume3 Month | 59,070 |
| Average Volume | 59,070 |
| Average Volume10Days | 53,620 |
| Beta | 0.041 |
| Bid | 1.39 |
| Bid Size | 1 |
| Book Value | 2.822 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.44 |
| Current Ratio | 8.82 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.465 |
| Day Low | 1.42 |
| Debt To Equity | 10.095 |
| Display Name | IN8bio |
| Earnings Timestamp End | 1,754,596,800 |
| Earnings Timestamp Start | 1,754,596,800 |
| Ebitda | -18,090,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.56 |
| Enterprise Value | -10,130,192 |
| Eps Current Year | -2.49667 |
| Eps Forward | -1.5075 |
| Eps Trailing Twelve Months | -4.44 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.673 |
| Fifty Day Average Change | -0.23299992 |
| Fifty Day Average Change Percent | -0.13927072 |
| Fifty Two Week Change Percent | -70.88354 |
| Fifty Two Week High | 5.82 |
| Fifty Two Week High Change | -4.38 |
| Fifty Two Week High Change Percent | -0.7525773 |
| Fifty Two Week Low | 1.17 |
| Fifty Two Week Low Change | 0.2700001 |
| Fifty Two Week Low Change Percent | 0.23076932 |
| Fifty Two Week Range | 1.17 - 5.82 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 7,029,344 |
| Forward Eps | -1.5075 |
| Forward P E | -0.95522386 |
| Free Cashflow | -5,547,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.20785 |
| Held Percent Institutions | 0.32784 |
| Implied Shares Outstanding | 9,847,090 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,749,168,000 |
| Last Split Factor | 1:30 |
| Long Business Summary | IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York. |
| Long Name | IN8bio, Inc. |
| Market | us_market |
| Market Cap | 14,179,810 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_556676116 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -19,440,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 14,278,279 |
| Number Of Analyst Opinions | 4 |
| Open | 1.4603 |
| Operating Cashflow | -12,712,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 646 600 6438 |
| Previous Close | 1.45 |
| Price Eps Current Year | -0.5767683 |
| Price Hint | 4 |
| Price To Book | 0.51027644 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.571 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.00999999 |
| Regular Market Change Percent | -0.689654 |
| Regular Market Day High | 1.465 |
| Regular Market Day Low | 1.42 |
| Regular Market Day Range | 1.42 - 1.465 |
| Regular Market Open | 1.4603 |
| Regular Market Previous Close | 1.45 |
| Regular Market Price | 1.44 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 18,586 |
| Return On Assets | -0.46643 |
| Return On Equity | -0.92491996 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 9,847,089 |
| Shares Percent Shares Out | 0.0301 |
| Shares Short | 296,110 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 138,633 |
| Short Name | IN8bio, Inc. |
| Short Percent Of Float | 0.0337 |
| Short Ratio | 3.85 |
| Source Interval | 15 |
| State | NY |
| Symbol | INAB |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 6.25 |
| Target Median Price | 5.5 |
| Total Cash | 27,092,000 |
| Total Cash Per Share | 2.751 |
| Total Debt | 2,782,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.97989 |
| Two Hundred Day Average Change | -0.53988993 |
| Two Hundred Day Average Change Percent | -0.27268684 |
| Type Disp | Equity |
| Volume | 18,586 |
| Website | https://in8bio.com |
| Zip | 10,118 |